Bausch & Lomb Surgical To Commence Catarex Clinical Trials In Mid-1999
This article was originally published in The Gray Sheet
Bausch & Lomb Surgical will initiate clinical trials to evaluate Optex Ophthalmologics' Catarex cataract-removal system in mid 1999. B&L and Optex parent Atlantic Pharmaceuticals jointly reported May 14 the signing of a multi-year license and development agreement related to the ophthalmic device.
You may also be interested in...
Can Atlas Biomed unlock Japan's self-care market with its direct-to-consumer DNA and microbiome tests? HBW Insight catches up with the company's co-founder and CEO to discuss this and also how Atlas has been driving its European expansion plans despite coronavirus.
France's ANSES warns women using oral contraceptives not to use a supplement marketed by UK firm Hairburst after linking the product's consumption to two cases of severe acute hepatitis.
A lower first dose boosted the vaccine’s efficacy result, but AstraZeneca has conceded that this has to be proven in a separate trial. In the meantime, the UK government has asked the regulator to assess the vaccine under a special health emergency provision.